Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals, Inc. - Common Stock (NQ:SYRS)

0.1172 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Syros Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros to Present at JMP Securities Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Virtual Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
From Syros Pharmaceuticals
Via Business Wire
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
From Syros Pharmaceuticals
Via Business Wire
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
From Syros Pharmaceuticals
Via Business Wire
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
From Syros Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.